Integrated Chromosome 19 Transcriptomic and Proteomic Data Sets Derived from Glioma Cancer Stem-Cell Lines

One subproject within the global Chromosome 19 Consortium is to
define chromosome 19 gene and protein expression in glioma-derived
cancer stem cells (GSCs). Chromosome 19 is notoriously linked to glioma
by 1p/19q codeletions, and clinical tests are established to detect
that specific aberration. GSCs are tumor-initiating cells and are
hypothesized to provide a repository of cells in tumors that can self-replicate
and be refractory to radiation and chemotherapeutic agents developed
for the treatment of tumors. In this pilot study, we performed RNA-Seq,
label-free quantitative protein measurements in six GSC lines, and
targeted transcriptomic analysis using a chromosome 19-specific microarray
in an additional six GSC lines. The data have been deposited to
the ProteomeXchange with identifier PXD000563. Here we present insights
into differences in GSC gene and protein expression, including the
identification of proteins listed as having no or low evidence at
the protein level in the Human Protein Atlas, as correlated to chromosome
19 and GSC subtype. Furthermore, the upregulation of proteins downstream
of adenovirus-associated viral integration site 1 (AAVS1) in GSC11
in response to oncolytic adenovirus treatment was demonstrated. Taken
together, our results may indicate new roles for chromosome 19, beyond
the 1p/19q codeletion, in the future of personalized medicine for
glioma patients.